GM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast Cancer

This study is testing whether a drug called GM1 (a naturally occurring substance) can prevent nerve damage in the hands and feet — a painful side effect called peripheral neuropathy — in women with breast cancer who are receiving a type of chemotherapy called nab-paclitaxel (albumin-bound paclitaxel). **You may be eligible if...** - You are a woman aged 18 to 75 with a confirmed breast cancer diagnosis - You are planned to receive nab-paclitaxel as part of your chemotherapy treatment - Your blood sugar is well controlled (HbA1c under 7.0%) - Your organs (heart, liver, kidneys) are functioning adequately **You may NOT be eligible if...** - You already have any nerve damage or tingling in your hands/feet - You have other known risk factors for nerve damage unrelated to chemotherapy - You have a history of another cancer (other than breast) - You have HIV, active hepatitis B or C, syphilis, or hereditary fat metabolism disorders - You have uncontrolled heart or blood vessel disease Talk to your doctor to see if this trial is right for you.